FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968938093> ?p ?o ?g. }

• W1968938093 endingPage "26" @default.
• W1968938093 startingPage "17" @default.
• W1968938093 abstract "Background The artificial pancreas is an emerging technology for the treatment of type 1 diabetes and two configurations have been proposed: single-hormone (insulin alone) and dual-hormone (insulin and glucagon). We aimed to delineate the usefulness of glucagon in the artificial pancreas system. Methods We did a randomised crossover trial of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy (continuous subcutaneous insulin infusion) in participants aged 12 years or older with type 1 diabetes. Participants were assigned in a 1:1:1:1:1:1 ratio with blocked randomisation to the three interventions and attended a research facility for three 24-h study visits. During visits when the patient used the single-hormone artificial pancreas, insulin was delivered based on glucose sensor readings and a predictive dosing algorithm. During dual-hormone artificial pancreas visits, glucagon was also delivered during low or falling glucose. During conventional insulin pump therapy visits, patients received continuous subcutaneous insulin infusion. The study was not masked. The primary outcome was the time for which plasma glucose concentrations were in the target range (4·0–10·0 mmol/L for 2 h postprandially and 4·0–8·0 mmol/L otherwise). Hypoglycaemic events were defined as plasma glucose concentration of less than 3·3 mmol/L with symptoms or less than 3·0 mmol/L irrespective of symptoms. Analysis was by modified intention to treat, in which we included data for all patients who completed at least two visits. A p value of less than 0·0167 (0·05/3) was regarded as significant. This trial is registered with ClinicalTrials.gov, number NCT01754337. Findings The mean proportion of time spent in the plasma glucose target range over 24 h was 62% (SD 18), 63% (18), and 51% (19) with single-hormone artificial pancreas, dual-hormone artificial pancreas, and conventional insulin pump therapy, respectively. The mean difference in time spent in the target range between single-hormone artificial pancreas and conventional insulin pump therapy was 11% (17; p=0·002) and between dual-hormone artificial pancreas and conventional insulin pump therapy was 12% (21; p=0·00011). There was no difference (15; p=0·75) in the proportion of time spent in the target range between the single-hormone and dual-hormone artificial pancreas systems. There were 52 hypoglycaemic events with conventional insulin pump therapy (12 of which were symptomatic), 13 with the single-hormone artificial pancreas (five of which were symptomatic), and nine with the dual-hormone artificial pancreas (0 of which were symptomatic); the number of nocturnal hypoglycaemic events was 13 (0 symptomatic), 0, and 0, respectively. Interpretation Single-hormone and dual-hormone artificial pancreas systems both provided better glycaemic control than did conventional insulin pump therapy. The single-hormone artificial pancreas might be sufficient for hypoglycaemia-free overnight glycaemic control. Funding Canadian Diabetes Association; Fondation J A De Sève; Juvenile Diabetes Research Foundation; and Medtronic. The artificial pancreas is an emerging technology for the treatment of type 1 diabetes and two configurations have been proposed: single-hormone (insulin alone) and dual-hormone (insulin and glucagon). We aimed to delineate the usefulness of glucagon in the artificial pancreas system. We did a randomised crossover trial of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy (continuous subcutaneous insulin infusion) in participants aged 12 years or older with type 1 diabetes. Participants were assigned in a 1:1:1:1:1:1 ratio with blocked randomisation to the three interventions and attended a research facility for three 24-h study visits. During visits when the patient used the single-hormone artificial pancreas, insulin was delivered based on glucose sensor readings and a predictive dosing algorithm. During dual-hormone artificial pancreas visits, glucagon was also delivered during low or falling glucose. During conventional insulin pump therapy visits, patients received continuous subcutaneous insulin infusion. The study was not masked. The primary outcome was the time for which plasma glucose concentrations were in the target range (4·0–10·0 mmol/L for 2 h postprandially and 4·0–8·0 mmol/L otherwise). Hypoglycaemic events were defined as plasma glucose concentration of less than 3·3 mmol/L with symptoms or less than 3·0 mmol/L irrespective of symptoms. Analysis was by modified intention to treat, in which we included data for all patients who completed at least two visits. A p value of less than 0·0167 (0·05/3) was regarded as significant. This trial is registered with ClinicalTrials.gov, number NCT01754337. The mean proportion of time spent in the plasma glucose target range over 24 h was 62% (SD 18), 63% (18), and 51% (19) with single-hormone artificial pancreas, dual-hormone artificial pancreas, and conventional insulin pump therapy, respectively. The mean difference in time spent in the target range between single-hormone artificial pancreas and conventional insulin pump therapy was 11% (17; p=0·002) and between dual-hormone artificial pancreas and conventional insulin pump therapy was 12% (21; p=0·00011). There was no difference (15; p=0·75) in the proportion of time spent in the target range between the single-hormone and dual-hormone artificial pancreas systems. There were 52 hypoglycaemic events with conventional insulin pump therapy (12 of which were symptomatic), 13 with the single-hormone artificial pancreas (five of which were symptomatic), and nine with the dual-hormone artificial pancreas (0 of which were symptomatic); the number of nocturnal hypoglycaemic events was 13 (0 symptomatic), 0, and 0, respectively. Single-hormone and dual-hormone artificial pancreas systems both provided better glycaemic control than did conventional insulin pump therapy. The single-hormone artificial pancreas might be sufficient for hypoglycaemia-free overnight glycaemic control." @default.
• W1968938093 created "2016-06-24" @default.
• W1968938093 creator A5020314374 @default.
• W1968938093 creator A5026585166 @default.
• W1968938093 creator A5034990765 @default.
• W1968938093 creator A5039349666 @default.
• W1968938093 creator A5049930175 @default.
• W1968938093 creator A5087727187 @default.
• W1968938093 date "2015-01-01" @default.
• W1968938093 modified "2023-10-16" @default.
• W1968938093 title "Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial" @default.
• W1968938093 cites W1752045965 @default.
• W1968938093 cites W1825118944 @default.
• W1968938093 cites W1968405174 @default.
• W1968938093 cites W1982250075 @default.
• W1968938093 cites W2021089415 @default.
• W1968938093 cites W2023792256 @default.
• W1968938093 cites W2064863602 @default.
• W1968938093 cites W2074531985 @default.
• W1968938093 cites W2083628344 @default.
• W1968938093 cites W2089597695 @default.
• W1968938093 cites W2102877966 @default.
• W1968938093 cites W2124282046 @default.
• W1968938093 cites W2135887483 @default.
• W1968938093 cites W2142433802 @default.
• W1968938093 cites W2146467643 @default.
• W1968938093 cites W2154010909 @default.
• W1968938093 cites W2158609480 @default.
• W1968938093 cites W2170283323 @default.
• W1968938093 cites W2170627020 @default.
• W1968938093 cites W2171969247 @default.
• W1968938093 cites W2315881257 @default.
• W1968938093 cites W2337375610 @default.
• W1968938093 cites W2769264260 @default.
• W1968938093 cites W4253337782 @default.
• W1968938093 doi "https://doi.org/10.1016/s2213-8587(14)70226-8" @default.
• W1968938093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25434967" @default.
• W1968938093 hasPublicationYear "2015" @default.
• W1968938093 type Work @default.
• W1968938093 sameAs 1968938093 @default.
• W1968938093 citedByCount "189" @default.
• W1968938093 countsByYear W19689380932014 @default.
• W1968938093 countsByYear W19689380932015 @default.
• W1968938093 countsByYear W19689380932016 @default.
• W1968938093 countsByYear W19689380932017 @default.
• W1968938093 countsByYear W19689380932018 @default.
• W1968938093 countsByYear W19689380932019 @default.
• W1968938093 countsByYear W19689380932020 @default.
• W1968938093 countsByYear W19689380932021 @default.
• W1968938093 countsByYear W19689380932022 @default.
• W1968938093 countsByYear W19689380932023 @default.
• W1968938093 crossrefType "journal-article" @default.
• W1968938093 hasAuthorship W1968938093A5020314374 @default.
• W1968938093 hasAuthorship W1968938093A5026585166 @default.
• W1968938093 hasAuthorship W1968938093A5034990765 @default.
• W1968938093 hasAuthorship W1968938093A5039349666 @default.
• W1968938093 hasAuthorship W1968938093A5049930175 @default.
• W1968938093 hasAuthorship W1968938093A5087727187 @default.
• W1968938093 hasConcept C126322002 @default.
• W1968938093 hasConcept C134018914 @default.
• W1968938093 hasConcept C142724271 @default.
• W1968938093 hasConcept C204787440 @default.
• W1968938093 hasConcept C27081682 @default.
• W1968938093 hasConcept C2777180221 @default.
• W1968938093 hasConcept C2778563252 @default.
• W1968938093 hasConcept C2778764654 @default.
• W1968938093 hasConcept C2779306644 @default.
• W1968938093 hasConcept C2779794567 @default.
• W1968938093 hasConcept C2780353609 @default.
• W1968938093 hasConcept C2781232474 @default.
• W1968938093 hasConcept C555293320 @default.
• W1968938093 hasConcept C71315377 @default.
• W1968938093 hasConcept C71924100 @default.
• W1968938093 hasConcept C87813604 @default.
• W1968938093 hasConcept C90924648 @default.
• W1968938093 hasConceptScore W1968938093C126322002 @default.
• W1968938093 hasConceptScore W1968938093C134018914 @default.
• W1968938093 hasConceptScore W1968938093C142724271 @default.
• W1968938093 hasConceptScore W1968938093C204787440 @default.
• W1968938093 hasConceptScore W1968938093C27081682 @default.
• W1968938093 hasConceptScore W1968938093C2777180221 @default.
• W1968938093 hasConceptScore W1968938093C2778563252 @default.
• W1968938093 hasConceptScore W1968938093C2778764654 @default.
• W1968938093 hasConceptScore W1968938093C2779306644 @default.
• W1968938093 hasConceptScore W1968938093C2779794567 @default.
• W1968938093 hasConceptScore W1968938093C2780353609 @default.
• W1968938093 hasConceptScore W1968938093C2781232474 @default.
• W1968938093 hasConceptScore W1968938093C555293320 @default.
• W1968938093 hasConceptScore W1968938093C71315377 @default.
• W1968938093 hasConceptScore W1968938093C71924100 @default.
• W1968938093 hasConceptScore W1968938093C87813604 @default.
• W1968938093 hasConceptScore W1968938093C90924648 @default.
• W1968938093 hasFunder F4320306172 @default.
• W1968938093 hasFunder F4320309829 @default.
• W1968938093 hasIssue "1" @default.
• W1968938093 hasLocation W19689380931 @default.
• W1968938093 hasLocation W19689380932 @default.
• W1968938093 hasOpenAccess W1968938093 @default.

• next